7th Dec 2015 07:59
LONDON (Alliance News) - Biofrontera AG said Monday that its Ameluz skin cancer treatment has been granted marketing approval in Switzerland.
The biopharmaceutical company said that it is now preparing to launch the product in spring 2016, and in parallel its Swiss partner Louis Widmer SA has applied for reimbursement which will be decided during the next year.
"The approval by the Swissmedic marks another important milestone towards the global commercialization of Ameluz, and we are delighted that the innovative photodynamic therapy with its outstanding efficacy in the treatment of actinic keratoses will be available to patients in Switzerland in the spring," said Chief Executive Officer Hermann Lübbert in a statement.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
B8F.L